[go: up one dir, main page]

WO2005054510A3 - Prediction de la receptivite et des resultats du traitement anti-oestrogenique du cancer du sein metastatique - Google Patents

Prediction de la receptivite et des resultats du traitement anti-oestrogenique du cancer du sein metastatique Download PDF

Info

Publication number
WO2005054510A3
WO2005054510A3 PCT/IB2004/004405 IB2004004405W WO2005054510A3 WO 2005054510 A3 WO2005054510 A3 WO 2005054510A3 IB 2004004405 W IB2004004405 W IB 2004004405W WO 2005054510 A3 WO2005054510 A3 WO 2005054510A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
outcome
metastatic breast
estrogen therapy
predicting response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/004405
Other languages
English (en)
Other versions
WO2005054510A2 (fr
Inventor
Petronella M J J Berns
Maurice P H M Janssen
John A Foekens
Joannes G M Klijn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus University Medical Center
Original Assignee
Erasmus University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University Medical Center filed Critical Erasmus University Medical Center
Priority to US10/581,611 priority Critical patent/US20080113345A1/en
Priority to NZ547955A priority patent/NZ547955A/en
Priority to EP04816623A priority patent/EP1699937A2/fr
Priority to AU2004294527A priority patent/AU2004294527A1/en
Publication of WO2005054510A2 publication Critical patent/WO2005054510A2/fr
Publication of WO2005054510A3 publication Critical patent/WO2005054510A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des signatures géniques, des gènes marqueurs spécifiques et des dosages diagnostiques permettant de prédire une survie sans évolution et une réponse objective au traitement anti-oestrogénique, par exemple au tamoxifène, chez des patientes atteintes du cancer du sein récidivant.
PCT/IB2004/004405 2003-12-05 2004-12-03 Prediction de la receptivite et des resultats du traitement anti-oestrogenique du cancer du sein metastatique Ceased WO2005054510A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/581,611 US20080113345A1 (en) 2003-12-05 2004-12-03 Predicting Response And Outcome Of Metastatic Breast Cancer Anti-Estrogen Therapy
NZ547955A NZ547955A (en) 2003-12-05 2004-12-03 Predicting response and outcome of metastatic breast cancer anti-estrogen therapy
EP04816623A EP1699937A2 (fr) 2003-12-05 2004-12-03 Prediction de la receptivite et des resultats du traitement anti-oestrogenique du cancer du sein metastatique
AU2004294527A AU2004294527A1 (en) 2003-12-05 2004-12-03 Predicting response and outcome of metastatic breast cancer anti-estrogen therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52760803P 2003-12-05 2003-12-05
US60/527,608 2003-12-05

Publications (2)

Publication Number Publication Date
WO2005054510A2 WO2005054510A2 (fr) 2005-06-16
WO2005054510A3 true WO2005054510A3 (fr) 2005-07-28

Family

ID=34652497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/004405 Ceased WO2005054510A2 (fr) 2003-12-05 2004-12-03 Prediction de la receptivite et des resultats du traitement anti-oestrogenique du cancer du sein metastatique

Country Status (5)

Country Link
US (1) US20080113345A1 (fr)
EP (1) EP1699937A2 (fr)
AU (1) AU2004294527A1 (fr)
NZ (1) NZ547955A (fr)
WO (1) WO2005054510A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084992A2 (fr) * 2006-01-19 2007-07-26 The University Of Chicago Marqueurs prédictifs utilisés à des fins de pronostic et de traitement et leurs méthodes d'utilisation
WO2008133493A1 (fr) * 2007-04-27 2008-11-06 Erasmus University Medical Center Rotterdam Prédiction de la réactivité à un traitement anti-œstrogénique dans le cancer du sein
US20120094859A1 (en) * 2010-10-19 2012-04-19 Eva Redei Methods for detection of depressive disorders
WO2015093948A2 (fr) * 2013-12-17 2015-06-25 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Moyens et procédés de typage d'une patiente atteinte d'un cancer du sein et assignation d'un thérapie basée sur ce typage
KR102194536B1 (ko) * 2019-06-10 2020-12-23 연세대학교 산학협력단 타목시펜의 반응성 예측용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068579A2 (fr) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits tels que des dosages d'acides nucleiques comprenant une majorite d'exons ou de transcrits humains, destines a detecter l'expression et pouvant avoir d'autres applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504222B2 (en) * 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1668354A2 (fr) * 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Methode de diagnostic du cancer du sein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068579A2 (fr) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits tels que des dosages d'acides nucleiques comprenant une majorite d'exons ou de transcrits humains, destines a detecter l'expression et pouvant avoir d'autres applications

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Affymetrix GeneChip Human Genome U95 Set HG-U95A", GENBANK GEO, 11 March 2002 (2002-03-11), XP002293987 *
DATABASE EMBL [online] 3 February 2004 (2004-02-03), "Sequence 10220 from Patent WO02068579.", XP002321906, retrieved from EBI accession no. EM_PAT:CQ724286 Database accession no. CQ724286 *
DATABASE EMBL [online] 3 February 2004 (2004-02-03), "Sequence 15057 from Patent WO02068579.", XP002321905, retrieved from EBI accession no. EM_PAT:CQ729123 Database accession no. CQ729123 *
DATABASE EMBL [online] 3 February 2004 (2004-02-03), "Sequence 3748 from Patent WO02068579.", XP002321904, retrieved from EBI accession no. EM_PAT:CQ717814 Database accession no. CQ717814 *
DATABASE EMBL [online] 3 February 2004 (2004-02-03), "Sequence 4515 from Patent WO02068579.", XP002321907, retrieved from EBI accession no. EM_PAT:CQ718581 Database accession no. CQ718581 *
DOWSETT MITCH: "Biomarker investigations from the ATAC trial: the role of TA01.", BREAST CANCER RESEARCH AND TREATMENT. 2004, vol. 87 Suppl 1, 2004, pages S11 - S18, XP002321903, ISSN: 0167-6806 *
JANSEN M ET AL: "Molecular classification of tamoxifen-responsive and -resistant breast carcinomas by gene expression profiling.", BREAST CANCER RESEARCH AND TREATMENT, vol. 82, no. Supplement 1, November 2003 (2003-11-01), & 26TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM; SAN ANTONIO, TX, USA; DECEMBER 03-06, 2003, pages S14, XP002321901, ISSN: 0167-6806 *
JANSEN MAURICE P H M ET AL: "Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 1 FEB 2005, vol. 23, no. 4, 1 February 2005 (2005-02-01), pages 732 - 740, XP009045184, ISSN: 0732-183X *
LOS GERRIT ET AL: "Using mRNA expression profiling to determine anticancer drug efficacy", CYTOMETRY, vol. 47, no. 1, 1 January 2002 (2002-01-01), pages 66 - 71, XP002321902, ISSN: 0196-4763 *
MA X-J ET AL: "A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen", CANCER CELL, XX, US, vol. 5, no. 6, June 2004 (2004-06-01), pages 607 - 616, XP002317299, ISSN: 1535-6108 *
PAIK S ET AL: "MULTI-GENE RT-PCR ASSAY FOR PREDICTING RECURRENCE IN NODE NEGATIVE BREAST CANCER PATIENTS-NSABP STUDIES B-20 AND B-14", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 82, no. SUPPL 1, 3 December 2003 (2003-12-03), pages S10 - S11,ABSTRN, XP001202622, ISSN: 0167-6806 *
See also references of EP1699937A2 *
STREEKUMAR A ET AL: "USING PROTEIN MICROARRAYS TO STUDY CANCER", BIOTECHNIQUES, EATON PUBLISHING, NATICK, US, no. SUPPL, December 2002 (2002-12-01), pages 46 - 53, XP009018820, ISSN: 0736-6205 *

Also Published As

Publication number Publication date
AU2004294527A1 (en) 2005-06-16
EP1699937A2 (fr) 2006-09-13
US20080113345A1 (en) 2008-05-15
NZ547955A (en) 2010-03-26
WO2005054510A2 (fr) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2006052731A3 (fr) Indicateurs moleculaires de pronostic de cancer du sein et prediction de reponse de traitement
WO2005100606A3 (fr) Marqueurs d'expression genique permettant de predire la reponse a la chimiotherapie
WO2004111603A3 (fr) Marqueurs de l'expression genetique permettant de predire la reponse une chimiotherapie
WO2004065583A3 (fr) Marqueurs d'expression genique pour le pronostic du cancer du sein
WO2005039382A3 (fr) Prediction de probabilite de la recurrence d'un cancer
EP2487254A3 (fr) Procédés à base de micro ARN et compositions pour le diagnostic et le traitement des cancers solides
EP2527472A3 (fr) Une lésion génétique associée à un cancer
WO2007084992A3 (fr) Marqueurs prédictifs utilisés à des fins de pronostic et de traitement et leurs méthodes d'utilisation
WO2008117314A3 (fr) Variants génétiques du chr2 et chr16 utilisés comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2008146309A3 (fr) Variantes génétiques sur les chr 5p12 et 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
GB0701676D0 (en) Methods and Kit for the Prgnosis of Breast Cancer
WO2006012361A3 (fr) Marqueurs genetiques de prediction de maladies et resultat therapeutique
WO2002024956A8 (fr) Marqueurs genetiques de tumeurs
WO2009009752A3 (fr) Modèles génétiques pour le classement des risques de cancer
WO2008037700A3 (fr) Procédés pour pronostiquer un cancer du sein
WO2004097052A3 (fr) Procedes de pronostic et de traitement de tumeurs solides
WO2008095049A3 (fr) Réactifs et procédés pour prédire une résistance aux médicaments
WO2004078035A3 (fr) Profiles d'expression pour le cancer du sein et methodes d'utilisation
WO2005001138A3 (fr) Survie apres cancer du sein et recurrence de ce type de cancer
WO2005054510A3 (fr) Prediction de la receptivite et des resultats du traitement anti-oestrogenique du cancer du sein metastatique
WO2009089548A3 (fr) Signature de risque de malignité provenant d'un tissu de sein histologiquement normal
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
EP1367138A3 (fr) Marqueurs pour le pronostic du cancer du sein
MXPA06014175A (es) Diagnostico o pronostico del curso del cancer de mama.
WO2004052184A3 (fr) Genes associes a la sensibilite et a la resistance au traitement par medicaments chimiotherapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 547955

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004816623

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004294527

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004294527

Country of ref document: AU

Date of ref document: 20041203

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004294527

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2004816623

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10581611

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10581611

Country of ref document: US